For most patients with chronic kidney failure, kidney transplantation has the greatest potential for restoring a healthy and productive life. The risk of acute rejection is the highest in the first months after transplantation (induction phase) and diminishes afterwards (maintenance phase). Immunosuppression should be at the highest level in the early period and reduced for long-term therapy. At present, conventional immunosuppressive protocols consist of the triple therapy: a calcineurin inhibitor, an adjunctive agent, corticosteroids. The development of new immunosuppressives drugs is aimed not only at improving short-term outcomes, but also achieving better safety, less nephrotoxicity and minimal side effects. Suppression of allograft rejection is the central issue in renal transplantation (RT). Thus, development of immunosuppressive agents is the key for successful allograft function. Immunosuppression agents in RT have evolved over the last six decades beginning with total lymphoid irradiation to the currently available immunosuppressive strategies, which have significantly reduced the incidence of acute rejection episodes and improved short-term graft and patient outcomes. However their use is associated with long-term graft dysfunction, hypertension, hyperlipidaemia, diabetes mellitus, infections and malignancies. Chronic antibody-mediated rejection and chronic allograft dysfunction still remain the major problems, often leading to graft loss and shortened long-term graft survival. Immunosuppressive agents are used for induction, maintenance and reversal of established rejection. The use of multidrug regimen tailored to the immunological risk of patient and adverse-effect profile of the drug provides the optimum outcomes. This review focuses on the evolution of immunosuppression agents used in RT over last six decades and highlights the newer agents under investigation.
immunosuppresants , kidney transplantation, induction therapy, maintenance therapy, Calcineurin inhibitors (CNI): Cyclosporine (CsA) and Tacrolimus (Tac)
International Journal of Trend in Scientific Research and Development - IJTSRD having
online ISSN 2456-6470. IJTSRD is a leading Open Access, Peer-Reviewed International
Journal which provides rapid publication of your research articles and aims to promote
the theory and practice along with knowledge sharing between researchers, developers,
engineers, students, and practitioners working in and around the world in many areas
like Sciences, Technology, Innovation, Engineering, Agriculture, Management and
many more and it is recommended by all Universities, review articles and short communications
in all subjects. IJTSRD running an International Journal who are proving quality
publication of peer reviewed and refereed international journals from diverse fields
that emphasizes new research, development and their applications. IJTSRD provides
an online access to exchange your research work, technical notes & surveying results
among professionals throughout the world in e-journals. IJTSRD is a fastest growing
and dynamic professional organization. The aim of this organization is to provide
access not only to world class research resources, but through its professionals
aim to bring in a significant transformation in the real of open access journals
and online publishing.